Index.php
Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, which includes the makers of Xarelto, have a duty to ensure that their drugs are reasonably secure for use - and failure to do so could be grounds for compensation. Our lawyers are working difficult to have these hurt by the drug the compensation they're entitled to.
Even though bleeding is a common complication linked with anticoagulants, it has been alleged that xarelto and internal bleeding is more harmful than traditional blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This implies that, within the occasion of an emergency, patients may be at threat for irreversible bleeding difficulties, including life-threatening internal and gastrointestinal hemorrhaging.
Should you or possibly a loved one suffered a critical bleeding event following taking Xarelto, you may have legal recourse. For more data, contact us today to have your case reviewed, cost-free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future medical bills, lost wages, pain and suffering and, in cases of death, funeral expenses. Moreover, they're seeking punitive damages, that are normally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs inside the lawsuits allege significant and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior inside the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.